ANIX Stock — Anixa Biosciences Inc

Anixa Biosciences Inc (ANIX)

Updated October 16, 2026.

ANIX is a Stock. Total return is -95.0% over the past 41.9 years.

Anixa Biosciences is a biotechnology company developing therapies and vaccines focused on cancer treatment, including a chimeric antigen receptor-T cell therapy for ovarian cancer and vaccine programs targeting breast cancer and other malignancies such as lung, colon, and prostate cancers. The company does not currently have an established distribution schedule. This stock may appeal to investors seeking exposure to early-stage oncology therapeutic development rather than current income.

ANIX performance

Price and return data through 2026-10-16.

Total return is -95.0% over the past 41.9 years. Over the past year its total return — price change plus distributions reinvested — is -39.3%. Its deepest 1-year drawdown was 55.0%.

ANIX key facts

Asset type

Stock

Asset class

Equity

Inception date

11/05/1984

Distribution frequency

None

Last close

$2.67 (as of 2026-10-16)

Market cap

$92,819,351

Average volume

123315.0

Beta

0.476

Payout ratio

0.0%

EPS

$-0.30

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ANIX risks and drawbacks

The deepest 1-year drawdown on record here is 55.0%.

Who may consider ANIX — and who may not

It is a weaker fit for investors who need monthly cash flow (ANIX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ANIX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions